Mckesson

McKesson Corporation, a pharmaceutical preparation manufacturing company headquartered in the US, has reported its greenhouse gas emissions. For the fiscal year 2025, the company's total reported emissions were approximately 36.25 billion kg CO2e. This figure is comprised of Scope 1 emissions of approximately 72.22 million kg CO2e, Scope 2 (market-based) emissions of approximately 119.94 million kg CO2e, and Scope 3 emissions amounting to approximately 36.08 billion kg CO2e.

In fiscal year 2024, McKesson's total emissions were approximately 32.75 billion kg CO2e, with Scope 1 emissions at roughly 79.85 million kg CO2e, Scope 2 (market-based) at approximately 152.13 million kg CO2e, and Scope 3 emissions at approximately 32.57 billion kg CO2e.

The company has established climate commitments, including a Science Based Targets initiative (SBTi) goal. McKesson commits to reduce absolute Scope 1 and 2 greenhouse gas emissions by 50.4% by fiscal year 2032, using a fiscal year 2020 baseline. Furthermore, McKesson aims for 70% of its suppliers, by spend for purchased goods and services, to have science-based targets in place by fiscal year 2027. These targets are set at the corporate level and are not cascaded from a parent organisation.